Japanese drugmaker Eisai opened two new plants--one targeting products for Asia and the other aimed at Europe--as part of its plans to expand its global manufacturing operations.
Germany's cost-effectiveness gatekeepers have delivered another blow to Eisai over the price of Fycompa. And the verdict, just the drugmaker's latest frustration over the epilepsy drug, has left it "speechless" and "dismayed."
Eisai and partner Helsinn secured the FDA's blessing to market Akynzeo, a combination treatment designed to prevent nasuea and vomiting among cancer patients undergoing chemotherapy.
Months after launching a regulatory battle to extend exclusivity for two of its best-selling products, Eisai won FDA approval for its Akynzeo drug to treat common side effects in patients undergoing chemotherapy.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...
What makes a 5-year exclusivity period? Under U.S. law, it's the 5 years after FDA starts the clock ticking. Eisai has no qualms about that. But the Japanese drugmaker says the agency started that clock much too soon for two of its products--and it's suing the FDA to change that.
Still suffering from the loss of patent protection on its big Alzheimer's drug Aricept, Japan's Eisai said today that the company had fired off a pair of applications for its new cancer drug to U.S. as well as European regulators.
Orexigen Therapeutics is on the verge of FDA approval for its obesity drug, after several long years of delay and frustration. But despite its late-to-the-party status--it's the third weight-loss pill in a new generation of treatments--it may end up winning the popularity contest.
The Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team.
Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team. On top of a new television ad push begun last month, the sales-force expansion is a one-two punch aimed at keeping prescription trends on the upswing.